Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 7, Issue 1, Pages 113-125Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2013.874943
Keywords
activin-A; bisphosphonates; bone disease; denosumab; RANKL; sclerostin; sotatercept; Wnt pathway
Categories
Funding
- Novartis
- Millenium
- Celgene
- Onyx
- Medtronics
- Acetylon
- Eli Lilly
- Lilly
Ask authors/readers for more resources
Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available